Abivax SA ADR (ABVX)
Featured in
High-Beta Stocks
Abivax SA ADR is a depositary receipt representing ordinary shares of Abivax SA, a clinical-stage biotechnology company focused on therapies designed to modulate the body’s immune response in chronic inflammatory diseases. The company’s lead candidate, obefazimod, is being developed in Phase 3 studies for moderately to severely active ulcerative colitis and in Phase 2b trials for Crohn’s disease. Abivax was incorporated in 2013 and is headquartered in Paris, France. The ADR is listed on NASDAQ under the ticker ABVX.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ABVX
|
$121.04
|
-9.3% Downside
|
Fair
|
$161.55
|
21.1% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
September 21, 2026
|
-30.4x
|
23.5x
|
2,053.4x
|
11.628 B
|
11.148 B
|
0.3%
|
84.6%
|
4.7
|
—
|
53.7%
|
